Allogene Therapeutics, Inc. (ALLO): Among the Rising Penny Stocks to Invest In Now

Yahoo Finance07:19 ET

Allogene Therapeutics Announces Participation in the Goldman Sachs Cell Therapy Day Conference

GlobeNewswireSep 30 08:30 ET

Express News | Allogene Therapeutics To Present Pre-Clinical Data Highlighting Potential Of ALLO-329 At ACR Convergence

BenzingaSep 26 08:32 ET

Gene Editing Therapeutics Market Report 2024, Featuring Profiles of Key Players Allogene Therapeutics, CRISPR Therapeutics, Intellia Therapeutics, Sangamo Therapeutics and Vertex Pharmaceuticals - ResearchAndMarkets.com

BusinesswireSep 16 10:10 ET

H.C. Wainwright Maintains Allogene Therapeutics(ALLO.US) With Buy Rating, Maintains Target Price $9

Moomoo NewsAug 15 06:31 ET · Ratings

CCORF Maintains Allogene Therapeutics(ALLO.US) With Buy Rating, Maintains Target Price $14

Moomoo NewsAug 14 07:34 ET · Ratings